Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a human IgG1? monoclonal antibody that was generated using human immunoglobulin (hu-Ig) transgenic mice. This monoclonal antibody specifically binds to the p40 subunit of IL-12 and IL-23, thus preventing their association with the IL-12R?1 receptor expressed on the NK cell and T cell surface and resulting in reduced IL-12 and IL-23 mediated signaling, activation, and cytokine production. The original monoclonal antibody was developed by Centocor and received FDA approval in 2009 for use in the treatment of psoriasis. Recently, it has been approved for the treatment of Crohns disease and ulcerative colitis.
Biovision | A2137 | Anti-IL-12? (Ustekinumab), Human IgG1 Antibody DataSheet
Antibody Target: IL-12?
Target Alternative Name: IL-12?, IL12?, IL 12?
Tag Line: A human monoclonal antibody that targets IL-12 and IL-23 by inhibiting their interaction with the receptor IL-12R?1 and thus disrupting IL-12 and IL-23 mediated signaling that is central to inflammatory diseases
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Ustekinumab
Accession #: DB05679
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS pH 7.5
Purification: Protein A purified
Application: In vitro studies
Positive Control:
Application And Usages: In vitro studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
